Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is already upon us. After all, we have made it this far, so we are determined to hang on — hang in? — for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy. So grab that cup of stimulation and get started. Our flavor today is blueberry cobbler, for those tracking our habits. Now, though, the time has come to get busy. So please grab your own cup and dig in to the items of interest assembled below. We hope you have a wonderful day, and please do keep in touch. …
U.S. Senate health committee chair Bernie Sanders called a vote to subpoena the chief of Novo Nordisk’s U.S. division over the company’s pricing of the popular diabetes drug Ozempic and the obesity drug Wegovy, STAT writes. The vote is scheduled for June 18. Sanders (I-Vt.) is seeking the appearance of Novo’s Doug Langa at a hearing next month. He launched an investigation into Novo Nordisk’s pricing practices in April, and, he said that the committee “reached out time and time again” to schedule Novo Nordisk’s voluntary appearance at a hearing to no avail. A Novo spokesperson said the company has responded to every request Sanders has made.
Data from Eli Lilly’s late-stage trial on its experimental obesity pill orforglipron are expected in April 2025, Reuters notes. The pill is part of a class of drugs known as incretins designed to mimic the action of the GLP-1 hormone, which helps regulate blood sugar, slow the rate at which the stomach empties of food, and decrease appetite. Drugs from the class are also being tested to treat Alzheimer’s. Patrik Jonsson, president of Lilly Diabetes and Obesity, speaking at a Goldman Sachs health care conference, said his company is not convinced that the drug will help with the disease itself, but might help with underlying conditions like obesity and stroke that lead to cognitive decline.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect